Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision | Next revisionBoth sides next revision | ||
mrepo:insight [08/01/2020 @ 11:01] – [Insight 46] adammoore | mrepo:insight [09/01/2020 @ 10:43] – adammoore | ||
---|---|---|---|
Line 24: | Line 24: | ||
=== Accessing Insight 46 data === | === Accessing Insight 46 data === | ||
---- | ---- | ||
- | Most of the Insight 46 data collected at the first wave of clinic visits is available via [[skylark: | + | Most of the Insight 46 data collected at the first wave of clinic visits is available via [[skylark: |
* {{apoe.pdf|ApoE status }} | * {{apoe.pdf|ApoE status }} | ||
Line 35: | Line 35: | ||
* {{Audiometry.pdf|Audiometry}} | * {{Audiometry.pdf|Audiometry}} | ||
\\ \\ | \\ \\ | ||
+ | For a quick way to view all available variables from the Insight 46 neuroscience sub-study, < | ||
---- | ---- | ||
Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, | Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, |